GlaxoSmithKline chops up mature drugs portfolio for $3B sale

GlaxoSmithKline ($GSK) may be hitting obstacles all over the world, what with bribery fines and probes, Advair rivals in Europe, and the like. But the U.K. drugmaker has managed to make progress on its plan to offload some of its older products: It's planning to sell off chunks of the portfolio in geographic areas, with Denmark's Lundbeck and India's Lupin are said to be in the running for regional pieces, likely in the U.S. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.